The A148T variant of the CDKN2A gene is not associated with melanoma risk in the French and Italian populations.
暂无分享,去创建一个
K. Peris | C. Lebbé | N. Basset-Seguin | P. Wolkenstein | B. Gérard | B. Grandchamp | N. Dupin | N. Soufir | P. Saiag | M. Fargnoli | B. Crickx | V. Descamps | M. Portela | D. Vitoux | A. Archimbaud | L. Ollivaud | T. Spica | F. Formicone
[1] J. A. Bishop,et al. A mutation hotspot at the p14ARF splice site , 2005, Oncogene.
[2] J. Kładny,et al. CDKN2A common variants and their association with melanoma risk: a population-based study. , 2005, Cancer research.
[3] E. Bar-Meir,et al. Genetics in melanoma. , 2004, The Israel Medical Association journal : IMAJ.
[4] J. Barrett,et al. An assessment of the CDKN2A variant Ala148Thr as a nevus/melanoma susceptibility allele. , 2002, The Journal of investigative dermatology.
[5] A. Howell,et al. Germline mutation of ARF in a melanoma kindred. , 2002, Human molecular genetics.
[6] K. Hemminki,et al. A single nucleotide polymorphism in the 3′untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare , 2001, International journal of cancer.
[7] D. Bishop,et al. Mutation screening of the CDKN2A promoter in melanoma families , 2000, Genes, chromosomes & cancer.
[8] P. Bruzzi,et al. Characterization of ligurian melanoma families and risk of occurrence of other neoplasia , 1999, International journal of cancer.
[9] D. Duffy,et al. CDKN2A variants in a population-based sample of Queensland families with melanoma. , 1999, Journal of the National Cancer Institute.
[10] D. Stoppa-Lyonnet,et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. , 1998, Human molecular genetics.
[11] K. Isselbacher,et al. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[12] R. Sutherland,et al. Cancer‐associated mis‐sense and deletion mutations impair p16INK4 CDK inhibitory activity , 1996, International journal of cancer.
[13] B. Peters,et al. Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. , 1995, Oncogene.
[14] N. Hayward,et al. Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. , 1995, Human molecular genetics.
[15] H. Varmus,et al. Mutations associated with familial melanoma impair p16INK4 function , 1995, Nature Genetics.
[16] W. Clark,et al. Germline p16 mutations in familial melanoma , 1994, Nature Genetics.
[17] M. Skolnick,et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus , 1994, Nature Genetics.